BL
CGEM icon

BFSG LLC’s Cullinan Oncology CGEM Stock Holding History

BFSG LLC’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$12.2K – 683
2024
Q4 		$12.2K Buy
+1,000
New +$14.4K ﹤0.01% 484

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFSG LLC's CGEM Position: Q1 2025 in Review

BFSG LLC sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 1,000 shares — an estimated $12.2K sold.

BFSG LLC first reported a position in CGEM in Q4 2024 and held it in 1 quarter. The position peaked at $12.2K in Q4 2024. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • BFSG LLC reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 1,000 Cullinan Oncology shares in Q1 2025, an estimated $12.2K.
  • BFSG LLC first reported a position in Cullinan Oncology in Q4 2024 and held it in 1 quarter.
  • BFSG LLC's Cullinan Oncology position peaked at $12.2K in Q4 2024.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.